Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer

Sheldon Fine, Charles Erlichman, Leonard Kaizer, David Warr, Tahany Gadalla

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Standard combination chemotherapy for metastatic breast cancer produces response rates between 30-60% with limited impact on survival. We undertook a phase II trial to determine the activity of 5 fluorouracil (5FU) and folinic acid (FA) in patients with measurable metastatic or recurrent breast cancer who had received no prior chemotherapy. Patients meeting the eligibility criteria received 5FU 370 mg/m2/day and FA 200 mg/m2/day for 5 days repeated every 28 days, toxicity allowing. Response defined by standard criteria was assessed every 8 weeks and toxicity according to WHO criteria was determined on every course. Thirty-three patients were entered on trial. Thirty-two patients were evaluable for response and 33 for toxicity. The dose limiting toxicity was stomatitis with 7/32, 19/32, and 5/32 patients experiencing grade 1, 2, and 3 toxicity. Grades 1 and 2 diarrhea occurred in 17/32 and 11/32 patients respectively. Myelosuppression was not significant. Two complete and 11 partial responses were observed. The overall response rate was 41% (95% CI, 24-58%). Responses were seen in soft tissue and visceral sites. Patients who had received adjuvant chemotherapy more than 6 months prior to receiving 5FU and FA responded also. Six of 29 patients receiving standard combination chemotherapy as second line treatment responded subsequently. We concluded: 1) 5FU and FA is an active combination in the treatment of breast cancer warranting further evaluation in combination with other drugs; 2) the dose-limiting toxicity of stomatitis is tolerable; 3) patients receiving 5FU and FA as first line therapy can respond to conventional combination chemotherapy as second line treatment.

Original languageEnglish (US)
Pages (from-to)205-209
Number of pages5
JournalBreast Cancer Research and Treatment
Volume30
Issue number2
DOIs
StatePublished - Jan 1994
Externally publishedYes

Fingerprint

Leucovorin
Fluorouracil
Breast Neoplasms
Combination Drug Therapy
Stomatitis
Therapeutics
Adjuvant Chemotherapy
Diarrhea
Drug Therapy
Survival

Keywords

  • 5FU
  • breast cancer
  • folinic acid
  • metastatic

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. / Fine, Sheldon; Erlichman, Charles; Kaizer, Leonard; Warr, David; Gadalla, Tahany.

In: Breast Cancer Research and Treatment, Vol. 30, No. 2, 01.1994, p. 205-209.

Research output: Contribution to journalArticle

Fine, Sheldon ; Erlichman, Charles ; Kaizer, Leonard ; Warr, David ; Gadalla, Tahany. / Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. In: Breast Cancer Research and Treatment. 1994 ; Vol. 30, No. 2. pp. 205-209.
@article{b8d9463f9f8043088ffb07ec980397ba,
title = "Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer",
abstract = "Standard combination chemotherapy for metastatic breast cancer produces response rates between 30-60{\%} with limited impact on survival. We undertook a phase II trial to determine the activity of 5 fluorouracil (5FU) and folinic acid (FA) in patients with measurable metastatic or recurrent breast cancer who had received no prior chemotherapy. Patients meeting the eligibility criteria received 5FU 370 mg/m2/day and FA 200 mg/m2/day for 5 days repeated every 28 days, toxicity allowing. Response defined by standard criteria was assessed every 8 weeks and toxicity according to WHO criteria was determined on every course. Thirty-three patients were entered on trial. Thirty-two patients were evaluable for response and 33 for toxicity. The dose limiting toxicity was stomatitis with 7/32, 19/32, and 5/32 patients experiencing grade 1, 2, and 3 toxicity. Grades 1 and 2 diarrhea occurred in 17/32 and 11/32 patients respectively. Myelosuppression was not significant. Two complete and 11 partial responses were observed. The overall response rate was 41{\%} (95{\%} CI, 24-58{\%}). Responses were seen in soft tissue and visceral sites. Patients who had received adjuvant chemotherapy more than 6 months prior to receiving 5FU and FA responded also. Six of 29 patients receiving standard combination chemotherapy as second line treatment responded subsequently. We concluded: 1) 5FU and FA is an active combination in the treatment of breast cancer warranting further evaluation in combination with other drugs; 2) the dose-limiting toxicity of stomatitis is tolerable; 3) patients receiving 5FU and FA as first line therapy can respond to conventional combination chemotherapy as second line treatment.",
keywords = "5FU, breast cancer, folinic acid, metastatic",
author = "Sheldon Fine and Charles Erlichman and Leonard Kaizer and David Warr and Tahany Gadalla",
year = "1994",
month = "1",
doi = "10.1007/BF00666065",
language = "English (US)",
volume = "30",
pages = "205--209",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer

AU - Fine, Sheldon

AU - Erlichman, Charles

AU - Kaizer, Leonard

AU - Warr, David

AU - Gadalla, Tahany

PY - 1994/1

Y1 - 1994/1

N2 - Standard combination chemotherapy for metastatic breast cancer produces response rates between 30-60% with limited impact on survival. We undertook a phase II trial to determine the activity of 5 fluorouracil (5FU) and folinic acid (FA) in patients with measurable metastatic or recurrent breast cancer who had received no prior chemotherapy. Patients meeting the eligibility criteria received 5FU 370 mg/m2/day and FA 200 mg/m2/day for 5 days repeated every 28 days, toxicity allowing. Response defined by standard criteria was assessed every 8 weeks and toxicity according to WHO criteria was determined on every course. Thirty-three patients were entered on trial. Thirty-two patients were evaluable for response and 33 for toxicity. The dose limiting toxicity was stomatitis with 7/32, 19/32, and 5/32 patients experiencing grade 1, 2, and 3 toxicity. Grades 1 and 2 diarrhea occurred in 17/32 and 11/32 patients respectively. Myelosuppression was not significant. Two complete and 11 partial responses were observed. The overall response rate was 41% (95% CI, 24-58%). Responses were seen in soft tissue and visceral sites. Patients who had received adjuvant chemotherapy more than 6 months prior to receiving 5FU and FA responded also. Six of 29 patients receiving standard combination chemotherapy as second line treatment responded subsequently. We concluded: 1) 5FU and FA is an active combination in the treatment of breast cancer warranting further evaluation in combination with other drugs; 2) the dose-limiting toxicity of stomatitis is tolerable; 3) patients receiving 5FU and FA as first line therapy can respond to conventional combination chemotherapy as second line treatment.

AB - Standard combination chemotherapy for metastatic breast cancer produces response rates between 30-60% with limited impact on survival. We undertook a phase II trial to determine the activity of 5 fluorouracil (5FU) and folinic acid (FA) in patients with measurable metastatic or recurrent breast cancer who had received no prior chemotherapy. Patients meeting the eligibility criteria received 5FU 370 mg/m2/day and FA 200 mg/m2/day for 5 days repeated every 28 days, toxicity allowing. Response defined by standard criteria was assessed every 8 weeks and toxicity according to WHO criteria was determined on every course. Thirty-three patients were entered on trial. Thirty-two patients were evaluable for response and 33 for toxicity. The dose limiting toxicity was stomatitis with 7/32, 19/32, and 5/32 patients experiencing grade 1, 2, and 3 toxicity. Grades 1 and 2 diarrhea occurred in 17/32 and 11/32 patients respectively. Myelosuppression was not significant. Two complete and 11 partial responses were observed. The overall response rate was 41% (95% CI, 24-58%). Responses were seen in soft tissue and visceral sites. Patients who had received adjuvant chemotherapy more than 6 months prior to receiving 5FU and FA responded also. Six of 29 patients receiving standard combination chemotherapy as second line treatment responded subsequently. We concluded: 1) 5FU and FA is an active combination in the treatment of breast cancer warranting further evaluation in combination with other drugs; 2) the dose-limiting toxicity of stomatitis is tolerable; 3) patients receiving 5FU and FA as first line therapy can respond to conventional combination chemotherapy as second line treatment.

KW - 5FU

KW - breast cancer

KW - folinic acid

KW - metastatic

UR - http://www.scopus.com/inward/record.url?scp=0028059046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028059046&partnerID=8YFLogxK

U2 - 10.1007/BF00666065

DO - 10.1007/BF00666065

M3 - Article

C2 - 7949219

AN - SCOPUS:0028059046

VL - 30

SP - 205

EP - 209

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -